Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion.

Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover into new drugs for cancer, neurology, and immunology.

The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.

By making large amounts of diverse data widely available, healthcare institutions can feel confident about the evaluation, creation, and validation of algorithms as they’re transitioned from ideation to use.

This new report sheds light on how the benefit consultants’ role has changed and details their perspective on the shifting employer healthcare landscape.

By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.

The founder and CEO of Unlearn.AI seeks to make clinical trials more efficient and less costly by leveraging its Digital Twin technology. If the company is successful, drugs could potentially be brought to market sooner and in a cost effective manner.

Do some people simply think the A in AI stands for Automation? Most likely the confusion is due to a lack of understanding of what AI truly is, combined with a strong desire to use the term for marketing purposes.

Epic announced that it will integrate Abridge’s clinical documentation tool into its EHR workflow. The startup’s generative AI tool listens to visits and creates a near-instant summary that adheres to physicians’ prototypical note structure.

Biotech startups raised $2.6 billion globally in the second quarter of this year, but that’s down nearly 46% compared to the same period last year, according to a report from Pitchbook. Capital is harder to find, and the report projects an uptick in M&A activity as companies run out of cash.

Flagship Pioneering-founded Alltrna is developing tRNA therapies to address genetic diseases driven by truncated versions of proteins. By addressing an aberrant genetic instruction underpinning many diseases, the startup is developing what it describes as a potential “universal solution.”

Senator Mark Warner (D-Virginia) penned a letter to Google leadership expressing concerns about Med-PaLM 2 — the company’s generative AI tool for healthcare providers that is currently being used by Mayo Clinic and other health systems. The letter requested that Google provide more clarity about its chatbot’s training, accuracy, ethical considerations and deployment in healthcare settings.

UltraSight, based in Israel, recently received a nod from the FDA to market its UltraSight AI Guidance product that can assist medical professionals without sonography experience in acquiring cardiac ultrasound images and allow for more widespread detection of heart diseases.

Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.

AI can index company narratives relative to strategy, opportunities, and threats, and create benchmarks to watch over time related to sentiment, intensity, and impressions. Ultimately these can be tied back to ROI and stakeholder value that move past typical marketing performance metrics or traditional brand metrics.

A schizophrenia drug candidate from partners Sumitomo Pharma and Otsuka Pharmaceutical failed to outperform a placebo in two Phase 3 studies. The compound is the most advanced program from a psychiatry and neurology collaboration spanning four drugs discovered by an artificial intelligence technology platform.

Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the possibility of joining forces with Nvidia in research.

Health systems need to turn their attention to technology that can improve staff retention by reducing employee burnout, according to HCA Divisional CIO Andy Draper. Here’s a look at what Parlance is doing to realize ROI with conversational AI.

With few workers entering a field dominated by older Gen X-ers and Baby Boomers, there’s a growing gap in skilled medical coders — people who read notes from doctors and apply appropriate codes for billing and reimbursement purposes. So many are turning to AI.

Scientists at Empress Therapeutics say molecules that co-evolved with humans over millennia are a promising source of new drugs. With its AI-driven technology platform, the Flagship Pioneering-founded startup finds them.

I interview Punit Singh Soni, CEO of Suki and Niall O’Connor, CTO, Cohere Health to evaluate two areas where AI can have an outsize impact: clinical documentation and prior authorization.

Losing sight of organizational goals and priorities and operating without a clear, supported plan can lead to a scatter-shot approach to AI investment that may duplicate investments, misallocate resources, and cause stakeholders to become cynical about AI’s value and potential.

Human tissues, coupled with AI that can deal with terabytes of data will blow mice models out of the water. With animal testing requirements finally removed, the pharma industry and its constituents can hope for faster innovation.

A conversation with Suchi Saria, associate professor of medicine at John Hopkins University and director of its Machine Learning and Healthcare Lab about responsible AI.

Although there is uncertainty and risk, the implementation of AI with the right compliance framework and infrastructure offers an exciting opportunity to transform healthcare into a new frontier with improved patient outcomes and increased efficiency.

At a time when the vast majority of people are just beginning to hear and learn about artificial intelligence, it is critical that technology executives make a concerted effort to reinforce its purpose and intent.

Although the flight check-in process is quick and easy, it lacks the intelligence and personalization that would make it truly exceptional. When I say I am optimistic that we can do better in healthcare, it’s because we are sitting on a wealth of data that lives, largely untapped, in the electronic health record

“Precision medicine” is a term we have heard a lot over the last two decades, […]

While human empathy will never be replaced, AI technologies and ChatGPT are providing new possibilities to help healthcare providers engage more efficiently with their patients and streamline administrative duties so physicians can focus more on their patients.